Yoji Nagashima is an expert in Oncology at Tokyo Women's Medical University Hospital (Japan). As of September 2026, ScienceLeadR ranks Yoji Nagashima in the top 1% of experts worldwide for Kidney Neoplasms and Carcinoma, and in the top 1% of experts in Japan for Urologic Neoplasms. Yoji Nagashima has authored 393 publications, the most recent in 2026. SLR score: 903 (community average: 125). How the SLR is computed.

LeadR Profile

903 ScienceLeadR Reputation 903
Network Map

Oncology

Subspecialties: Surgery - Gastroenterology - Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026

Source: PubMed

Yokohama City University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 393

Citations

Citations: 10 388 1st author: 6 Last author: 36 Unique author: 2


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Living-donor Kidney Transplantation After Resection of Mixed Epithelial and Stromal Tumor: A Positive Outcome Despite Not Observing the Recommended Waiting Period.
PMID 42388587 — neoplasms, kidney, kidney failure, chronic, diagnosis, kidney transplantation, nephroureterectomy, transplantation
Cancer Diagn Progn20260
ASPSCR1: TFE3 Fusion-Positive Epithelioid Angiomyolipoma/PEComa Lacking Melanocytic Markers: A Case Report.
PMID 42358469 — cells, perivascular epithelioid cell neoplasms, neoplasms, carcinoma, renal cell, kidney neoplasms, angiomyolipoma, epithelioid cells
IJU Case Rep20260
Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.
PMID 42256325 — cells, nephrectomy, carcinoma, renal cell, neoplasm metastasis, therapeutics, wounds and injuries
IJU Case Rep20260
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
PMID 42240722 — cells, safety, neoplasms, carcinoma, renal cell, biomarkers, therapeutics
Target Oncol20260
Parathyroid Carcinoma Disseminated Following Endoscopically-Assisted Surgery: A Case Report.
PMID 42137300 — cells, neoplasms, thyroid gland, neoplasm metastasis, therapeutics, mutation
Surg Case Rep20260

LeadR Networks

Main global connection map